Halozyme Therapeutics, Inc. $HALO Shares Sold by Linden Thomas Advisory Services LLC

Linden Thomas Advisory Services LLC decreased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,235 shares of the biopharmaceutical company’s stock after selling 646 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Halozyme Therapeutics were worth $1,833,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. State of New Jersey Common Pension Fund D lifted its stake in shares of Halozyme Therapeutics by 0.9% in the second quarter. State of New Jersey Common Pension Fund D now owns 42,473 shares of the biopharmaceutical company’s stock valued at $2,209,000 after purchasing an additional 384 shares during the period. Keeler Thomas Management LLC acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $983,000. AlphaQuest LLC lifted its stake in shares of Halozyme Therapeutics by 2,933.1% in the second quarter. AlphaQuest LLC now owns 5,308 shares of the biopharmaceutical company’s stock valued at $276,000 after purchasing an additional 5,133 shares during the period. Asset Management One Co. Ltd. acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $98,000. Finally, First Citizens Bank & Trust Co. acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $436,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity

In related news, Director Bernadette Connaughton sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total value of $294,720.00. Following the completion of the sale, the director directly owned 46,952 shares in the company, valued at approximately $3,459,423.36. The trade was a 7.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Nicole Labrosse sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the completion of the sale, the chief financial officer owned 24,306 shares of the company’s stock, valued at approximately $1,840,207.26. The trade was a 45.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 108,227 shares of company stock valued at $7,779,595 over the last 90 days. Insiders own 2.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 5th. Zacks Research cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday. JMP Securities lifted their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 6th. Finally, Morgan Stanley decreased their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research note on Monday, October 20th. Four analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $72.89.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $66.15 on Friday. The firm has a 50 day simple moving average of $71.71 and a 200-day simple moving average of $62.34. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The firm has a market cap of $7.74 billion, a PE ratio of 15.14, a P/E/G ratio of 0.35 and a beta of 1.16. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.31. The business had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company’s revenue was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.